senior medical correspondent elizabeth cohen joins us now. how promising is this new drug? and given the side effects, is it worth it in terms of what researchers are saying at this point? bianna, essentially that s what the u.s. food & drug administration has to decide. they fasttracked this drug, but the study authors themselves say that longer studies need to be done. so efficacy, first, what they did, they took 1800 people between the ages of 50 and 90 who had mild early stages of alzheimer s. hat goff a ploo seo, hat the dripping. the half that got the drug did see a decline, but 27% slower. also, the folks in the drug group they lower levels of amyloid.
Por que os intelectuais se sentem tentados a mandar na sociedade gazetadopovo.com.br - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazetadopovo.com.br Daily Mail and Mail on Sunday newspapers.